The Changing Landscape of Inflammatory Bowel Disease: East Meets West

Gastroenterology

Volumn 150, Issue 1, 2016, Pages 24-26

  Kaplan, Gilaad G ^a   Jess, Tine ^b  

^a UNIVERSITY OF CALGARY   (Canada)

^b STATENS SERUM INSTITUT   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

CHRONIC DISEASE; COLON RESECTION; CROHN DISEASE; EDITORIAL; EMERGENCY WARD; EVIDENCE BASED PRACTICE; GASTROENTEROLOGIST; HEALTH CARE NEED; HEALTH SERVICES RESEARCH; HOSPITALIZATION; HUMAN; INDUSTRIALIZATION; OBSERVATIONAL STUDY; OUTPATIENT; PERSONAL EXPERIENCE; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; RISK FACTOR; ULCERATIVE COLITIS; FEMALE; INFLAMMATORY BOWEL DISEASES; MALE;

FEMALE; HUMANS; INFLAMMATORY BOWEL DISEASES; MALE;

EID: 84952700582     PISSN: 00165085     EISSN: 15280012     Source Type: Journal    
DOI: 10.1053/j.gastro.2015.11.029     Document Type: Editorial

References (26)

1. D.J. Mulder, A.J. Noble, C.J. Justinich, and et al. A tale of two diseases: the history of inflammatory bowel disease J Crohns Colitis 8 2014 341 348
2. N.A. Molodecky, I.S. Soon, D.M. Rabi, and et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review Gastroenterology 142 2012 46 54 e42 quiz e30
3. G.G. Kaplan The global burden of IBD: from 2015 to 2025 Nat Rev Gastroenterol Hepatol 2015 Sep 1 [Epub ahead of print]
4. S.C. Ng, W. Tang, J.Y. Ching, and et al. Incidence and phenotype of inflammatory bowel disease based on results from the Asia-pacific Crohn's and colitis epidemiology study Gastroenterology 145 2013 158 165 e2
5. S.C. Ng, Z. Zeng, O. Niewiadomski, and et al. Early course of inflammatory bowel disease in a population-based inception cohort study from 8 countries in Asia and Australia Gastroenterology 150 2016 86 95
6. E.I. Benchimol, D.R. Mack, A. Guttmann, and et al. Inflammatory bowel disease in immigrants to Canada and their children: a population-based cohort study Am J Gastroenterol 110 2015 553 563
7. J.Z. Liu, S. van Sommeren, H. Huang, and et al. Association analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight shared genetic risk across populations Nat Genet 47 2015 979 986
8. A. Frolkis, L.A. Dieleman, H. Barkema, and et al. Environment and the inflammatory bowel diseases Can J Gastroenterol 27 2013 e18 e24
9. S.C. Ng, W. Tang, R.W. Leong, and et al. Environmental risk factors in inflammatory bowel disease: a population-based case-control study in Asia-Pacific Gut 64 2015 1063 1071
10. S.C. Ng, K.K. Tsoi, M.A. Kamm, and et al. Genetics of inflammatory bowel disease in Asia: systematic review and meta-analysis Inflamm Bowel Dis 18 2012 1164 1176
11. N.A. Molodecky, R. Panaccione, S. Ghosh, and et al. Challenges associated with identifying the environmental determinants of the inflammatory bowel diseases Inflamm Bowel Dis 17 2011 1792 1799
12. J. Burisch, T. Jess, M. Martinato, and et al. The burden of inflammatory bowel disease in Europe J Crohns Colitis 7 2013 322 337
13. M.D. Kappelman, S.L. Rifas-Shiman, C.Q. Porter, and et al. Direct health care costs of Crohn's disease and ulcerative colitis in US children and adults Gastroenterology 135 2008 1907 1913
14. A. Rocchi, E.I. Benchimol, C.N. Bernstein, and et al. Inflammatory bowel disease: a Canadian burden of illness review Can J Gastroenterol 26 2012 811 817
15. W.J. Sandborn, P. Rutgeerts, B.G. Feagan, and et al. Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab Gastroenterology 137 2009 1250 1260 quiz 1520
16. G.R. Lichtenstein, S. Yan, M. Bala, and et al. Remission in patients with Crohn's disease is associated with improvement in employment and quality of life and a decrease in hospitalizations and surgeries Am J Gastroenterol 99 2004 91 96
17. C. Smart, and C.P. Selinger The cost-effectiveness of infliximab in Crohn's disease Expert Rev Pharmacoecon Outcomes Res 14 2014 589 598
18. J.K. Lee, D.H. Tang, L. Mollon, and et al. Cost-effectiveness of biological agents used in ulcerative colitis Best Pract Res Clin Gastroenterol 27 2013 949 960
19. N. Nyboe Andersen, B. Pasternak, S. Basit, and et al. Association between tumor necrosis factor-alpha antagonists and risk of cancer in patients with inflammatory bowel disease JAMA 311 2014 2406 2413
20. N. Nyboe Andersen, B. Pasternak, N. Friis-Moller, and et al. Association between tumour necrosis factor-alpha inhibitors and risk of serious infections in people with inflammatory bowel disease: nationwide Danish cohort study BMJ 350 2015 h2809
21. J.F. Colombel, W.J. Sandborn, W. Reinisch, and et al. Infliximab, azathioprine, or combination therapy for Crohn's disease N Engl J Med 362 2010 1383 1395
22. A.B. Zwi, and A. Mills Health policy in less developed countries: past trends and future directions J Int Dev 7 1995 299 328
23. A.D. Frolkis, J. Dykeman, M.E. Negron, and et al. Risk of surgery for inflammatory bowel diseases has decreased over time: a systematic review and meta-analysis of population-based studies Gastroenterology 145 2013 996 1006
24. B. Bressler, J.K. Marshall, C.N. Bernstein, and et al. Clinical practice guidelines for the medical management of nonhospitalized ulcerative colitis: the Toronto consensus Gastroenterology 148 2015 1035 1058 e3
25. J.P. Terdiman, C.B. Gruss, J.J. Heidelbaugh, and et al. American Gastroenterological Association Institute guideline on the use of thiopurines, methotrexate, and anti-TNF-alpha biologic drugs for the induction and maintenance of remission in inflammatory Crohn's disease Gastroenterology 145 2013 1459 1463
26. M.E. Gerich, and D.P. McGovern Towards personalized care in IBD Nat Rev Gastroenterol Hepatol 11 2014 287 299